{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:18:59Z","timestamp":1778635139251,"version":"3.51.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/ogx.0b013e31819f992e","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T14:08:29Z","timestamp":1242914909000},"page":"345-350","source":"Crossref","is-referenced-by-count":12,"title":["The HPV Vaccines\u2014Which to Prefer?"],"prefix":"10.1097","volume":"64","author":[{"given":"Jacob","family":"Bornstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-23-20210212","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial.","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"R3-23-20210212","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial.","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"R4-23-20210212","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 45 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial.","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"R5-23-20210212","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital disease.","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"R6-23-20210212","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.","volume":"356","year":"2007","journal-title":"N Eng J Med"},{"key":"R7-23-20210212","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, 18) L1 like particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials.","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"R8-23-20210212","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus \u2013like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials.","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"key":"R9-23-20210212","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus like particle vaccine against infection with HPV 16 and 18 in young women: an interim analysis of a phase III double blind, randomized controlled trial.","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"R10-23-20210212","first-page":"158","article-title":"Sustained immunogenicity and high efficacy against HPV 16\/18 related 6.4 years in women vaccinated with cervarix.","volume":"109","author":"Harper","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R12-23-20210212","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/14750708.5.3.305","article-title":"Evaluating the potential benefits of universal worldwide human papillomavirus vaccination.","volume":"5","author":"Bosch","year":"2008","journal-title":"Therapy"},{"key":"R13-23-20210212","first-page":"S1","article-title":"HPV vaccines and screening in the prevention of cervical cancer.","volume":"24","year":"2006","journal-title":"Vaccine"},{"key":"R14-23-20210212","first-page":"156","article-title":"Human papillomavirus vaccine: the beginning of the end for cervical cancer.","volume":"9","author":"Bornstein","year":"2007","journal-title":"Isr Med Assoc J"},{"key":"R15-23-20210212","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/14712598.4.7.1129","article-title":"Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.","volume":"4","author":"Baldridge","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"R16-23-20210212","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV 16\/18 L1 VLP vaccine formulated with the MPL\/aluminum salt combination (ASO4) compared to aluminum salt only.","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"R17-23-20210212","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2008.05.036","article-title":"Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16\/18 vaccine: improving upon nature.","volume":"110","author":"Schwarz","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R18-23-20210212","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine.","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"R19-23-20210212","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ygyno.2008.06.029","article-title":"Impact of vaccination with Cervarix on subsequent HPV-16\/18 infection and cervical disease in women 15\u201325 years of age.","volume":"110","author":"Harper","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R20-23-20210212","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1542\/peds.112.6.1394","article-title":"Addressing parents\u2019 concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals?","volume":"112","author":"Offit","year":"2003","journal-title":"Pediatrics"},{"key":"R21-23-20210212","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bjc.6604146","article-title":"HPV and cervical cancer: screening or vaccination?","volume":"98","author":"Bosch","year":"2008","journal-title":"Br J Cancer"},{"key":"R22-23-20210212","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ygyno.2008.02.003","article-title":"Immunobiology of HPV and HPV vaccines.","volume":"109","author":"Stanley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R24-23-20210212","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ygyno.2008.06.027","article-title":"A review of cross-protection against oncogenic HPV by an HPV-16\/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.","volume":"110","author":"Jenkins","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R26-23-20210212","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.","volume":"7","author":"de Sanjos\u00e9","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"R27-23-20210212","doi-asserted-by":"crossref","first-page":"238","DOI":"10.5694\/j.1326-5377.2008.tb01593.x","article-title":"Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26?","volume":"188","author":"Skinner","year":"2008","journal-title":"Med J Aust"},{"key":"R30-23-20210212","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"R31-23-20210212","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1783\/147118908783332113","article-title":"Human papillomaviruses (HPV) vaccines: implementation and communication issues.","volume":"34","author":"Kane","year":"2008","journal-title":"J Fam Plann Reprod Health Care"},{"key":"R32-23-20210212","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1016\/j.vaccine.2007.07.018","article-title":"Cost utility analysis of vaccination against HPV in Israel.","volume":"25","author":"Ginsberg","year":"2007","journal-title":"Vaccine"}],"container-title":["Obstetrical & Gynecological Survey"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006254-200905000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:29:03Z","timestamp":1618036143000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006254-200905000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ogx.0b013e31819f992e","relation":{},"ISSN":["0029-7828"],"issn-type":[{"value":"0029-7828","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}